|
1
|
Steinman RM and Cohn ZA: Identification of
a novel cell type in peripheral lymphoid organs of mice. I
Morphology, quantitation, tissue distribution. J Exp Med.
137:1142–1162. 1973. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cella M, Sallusto F and Lanzavecchia A:
Origin, maturation and antigen presenting function of dendritic
cells. Curr Opin Immunol. 9:10–16. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hart DN: Dendritic cells: unique leukocyte
populations which control the primary immune response. Blood.
90:3245–3287. 1997.PubMed/NCBI
|
|
4
|
Steinman RM: The dendritic cell system and
its role in immunogenicity. Annu Rev Immunol. 9:271–296. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Banchereau J and Steinman RM: Dendritic
cells and the control of immunity. Nature. 392:245–252. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Baird JR, Fox BA, Sanders KL, et al:
Avirulent Toxoplasma gondii generates therapeutic antitumor
immunity by reversing immunosuppression in the ovarian cancer
microenvironment. Cancer Res. 73:3842–3851. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schuler G and Steinman RM: Dendritic cells
as adjuvants for immune-mediated resistance to tumors. J Exp Med.
186:1183–1187. 1997. View Article : Google Scholar
|
|
8
|
Gabrilovich D, Ciernik F and Carbone DP:
Dendritic cells in anti-tumor immune responses. I Defective antigen
presentation in tumor-bearinghosts. Cell Immunol. 170:101–110.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chaux P, Moutet M, Faivre J, Martin F and
Martin M: Inflammatory cells infiltrating human colorectal
carcinomas express HLA class II but not B7-1 and B7-2 costimulatory
molecules of the T-cell activation. Lab Invest. 74:975–983.
1996.PubMed/NCBI
|
|
10
|
Chaux P, Favre N, Martin M and Martin F:
Tumor-infiltrating dendritic cells are defective in their
antigen-presenting function and inducible B7 expression in rats.
Int J Cancer. 72:619–624. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gabrilovich DI, Corak J, Ciernik IF,
Kavanaugh D and Carbone DP: Decreased antigen presentation by
dendritic cells in patients with breast cancer. Clin Cancer Res.
3:483–490. 1997.PubMed/NCBI
|
|
12
|
Nestle FO, Burg G, Fah J, Wrone-Smith T
and Nickoloff BJ: Human sunlight-induced
basal-cell-carcinoma-associated dendritic cells are deficient in T
cell co-stimulatory molecules and are impaired as
antigen-presenting cells. Am J Pathol. 150:641–651. 1997.PubMed/NCBI
|
|
13
|
Gabrilovich DI, Nadaf S, Corak J,
Berzofsky JA and Carbone DP: Dendritic cells in antitumor immune
responses. II Dendritic cells grown from bone marrow precursors,
but not mature DC from tumor-bearing mice are effective antigen
carriers in the therapy of established tumors. Cell Immunol.
170:111–119. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gabrilovich DI, Chen HL, Girgis KR, et al:
Production of vascular endothelial growth factor by human tumors
inhibits the functional maturation of dendritic cells. Nat Med.
2:1096–1103. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ratta M, Fagnoni F, Curti A, et al:
Dendritic cells are functionally defective in multiple myeloma: the
role of interleukin-6. Blood. 100:230–237. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Um SH, Mulhall C, Alisa A, et al:
Alpha-fetoprotein impairs APC function and induces their apoptosis.
J Immunol. 173:1772–1778. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Péguet-Navarro J, Sportouch M, Popa I, et
al: Gangliosides from human melanoma tumors impair dendritic cell
differentiation from monocytes and induce their apoptosis. J
Immunol. 170:3488–3494. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sombroek CC, Stam AG, Masterson AJ, et al:
Prostanoids play a major role in the primary tumor-induced
inhibition of dendritic cell differentiation. J Immunol.
168:4333–4343. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bockorny B and Dasanu CA: Intrinsic immune
alterations in renal cell carcinoma and emerging immunotherapeutic
approaches. Expert Opin Biol Ther. 13:911–925. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Harimoto H, Shimizu M, Nakagawa Y,
Nakatsuka K, Wakabayashi A, Sakamoto C and Takahashi H:
Inactivation of tumor-specific CD8+ CTLs by
tumor-infiltrating tolerogenic dendritic cells. Immunol Cell Biol.
91:545–555. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Toi M, Taniguchi T, Yamamoto Y, Kurisaki
T, Suzuki H and Tominaga T: Clinical significance of the
determination of angiogenic actors. Eur J Cancer. 32A:2513–2519.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ellis LM and Fidler IJ: Angiogenesis and
metastasis. Eur J Cancer. 32A:2451–2460. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ferrara N and Davis-Smyth T: The biology
of vascular endothelial growth factor. Endocr Rev. 18:4–25. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Salven P, Mänpää H, Orpana A, Alitalo K
and Joensuu H: Serum vascular endothelial growth factor is often
elevated in disseminated cancer. Clin Cancer Res. 3:647–651.
1997.PubMed/NCBI
|
|
25
|
Ni YH, Wang ZY, Huang XF, et al: Effect of
siRNA-mediated downregulation of VEGF in Tca8113 cells on the
activity of monocyte-derived dendritic cells. Oncol Lett.
3:885–892. 2012.PubMed/NCBI
|
|
26
|
Hajrasouliha AR, Funaki T, Sadrai Z,
Hattori T, Chauhan SK and Dana R: Vascular endothelial growth
factor-C promotes alloimmunity by amplifying antigen-presenting
cell maturation and lymphangiogenesis. Invest Ophthalmol Vis Sci.
53:1244–1250. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Marti LC, Pavon L, Severino P, Sibov T,
Guilhen D and Moreira-Filho CA: Vascular endothelial growth
factor-A enhances indoleamine 2,3-dioxygenase expression by
dendritic cells and subsequently impacts lymphocyte proliferation.
Mem Inst Oswaldo Cruz. 109:70–79. 2014. View Article : Google Scholar :
|
|
28
|
Liu CZ, Zhang L, Chang XH, et al:
Overexpression and immunosuppressive functions of transforming
growth factor 1, vascular endothelial growth factor and
interleukin-10 in epithelial ovarian cancer. Chin J Cancer Res.
24:130–137. 2012. View Article : Google Scholar
|
|
29
|
Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S
and Muramatsu T: A small interfering RNA targeting vascular
endothelial growth factor as cancer therapeutics. Cancer Res.
64:3365–3370. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Walter S, Weinschenk T, Stenzl A, et al:
Multipeptide immune response to cancer vaccine IMA901 after
single-dose cyclophosphamide associates with longer patient
survival. Nat Med. 18:1254–1261. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cubillos-Ruiz JR, Baird JR, Tesone AJ, et
al: Reprogramming tumor-associated dendritic cells in vivo using
miRNA mimetics triggers protective immunity against ovarian cancer.
Cancer Res. 72:1683–1693. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gabrilovich DI, Ciernik IF and Carbone DP:
Dendritic cells in antitumor immune responses. I Defective antigen
presentation in tumor-bearing hosts. Cell Immunol. 170:101–110.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gabrilovich DI, Corak J, Ciernik IF,
Kavanaugh D and Carbone DP: Decreased antigen presentation by
dendritic cells in patients with breast cancer. Clin Cancer Res.
3:483–490. 1997.PubMed/NCBI
|
|
34
|
Gabrilovich DI, Chen HL, Girgis KR, et al:
Production of vascular endothelial growth factor by human tumors
inhibits the functional maturation of dendritic cells. Nat Med.
2:1096–1103. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mosca PJ, Hobeika AC, Colling K, et al:
Multiple signals are required for maturation of human dendritic
cells mobilized in vivo with Flt3 ligand. J Leukoc Biol.
72:546–553. 2002.PubMed/NCBI
|
|
36
|
Scarlett UK, Rutkowski MR, Rauwerdink AM,
et al: Ovarian cancer progression is controlled by phenotypic
changes in dendritic cells. J Exp Med. 209:495–506. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gabrilovich DI, Chen HL, Girgis KR, et al:
Production of vascular endothelial growth factor by human tumors
inhibits the functional maturation of dendritic cells. Nat Med.
2:1096–1103. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Woltman AM and van Kooten C: Functional
modulation of dendritic cells to suppress adaptive immune
responses. J Leukoc Biol. 73:428–441. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dikov MM, Ohm JE, Ray N, et al:
Differential roles of vascular endothelial growth factor receptors
1 and 2 in dendritic cell differentiation. J Immunol. 174:215–222.
2005. View Article : Google Scholar
|
|
40
|
Leung DW, Cachianes G, Kuang WJ, Goeddel
DV and Ferrara N: Vascular endothelial growth factor is a secreted
angiogenic mitogen. Science. 246:1306–1309. 1989. View Article : Google Scholar : PubMed/NCBI
|
